Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protocol 018 observational follow-up study of odanacatib in postmenopausal osteoporosis
2013-001526-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odanacatib in osteoporosis, sponsored by Merck & Co. Primary endpoints: Safety events during follow-up and End of trial safety status. Started Aug 2013; status: completed.
02
Drugs
odanacatib
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2013-001526-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001526-26.